<div id="readability-page-1"><p>MannKind (NASDAQ:MNKD - Get Free Report) is expected to announce its  Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Interested persons are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, February 23, 2026 at 4:00 PM ET.</p><h2>MannKind Stock Performance</h2><p>MNKD stock opened at $5.54 on Wednesday. The company's fifty day moving average price is $5.75 and its 200-day moving average price is $5.31. MannKind has a one year low of $3.38 and a one year high of $6.51. The company has a market capitalization of $1.70 billion, a PE ratio of 55.40 and a beta of 0.84. </p><h2>Wall Street Analyst Weigh In</h2><p>Several research firms have commented on MNKD. Zacks Research downgraded shares of MannKind from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, February 10th. HC Wainwright  reissued a &#34;buy&#34; rating and set a $11.00 price target on shares of MannKind in a research note on Monday, January 26th. Weiss Ratings  restated a &#34;hold (c)&#34; rating on shares of MannKind in a report on Thursday, January 22nd. Wells Fargo &amp; Company decreased their price objective on MannKind from $10.00 to $8.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, November 11th. Finally, Royal Bank Of Canada cut their target price on shares of MannKind from $8.00 to $7.50 and set an &#34;outperform&#34; rating for the company in a report on Tuesday, November 11th. One equities research analyst  has rated the stock with a Strong Buy rating, seven have issued  a Buy rating and two have issued  a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $10.06.</p><p><b>Check Out Our Latest Analysis on MNKD</b></p><h2>Insider Buying and Selling at MannKind</h2><p>In related news, CEO Michael Castagna sold 65,804 shares of MannKind stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $6.01, for a total transaction of $395,482.04. Following the completion of the transaction, the chief executive officer directly owned 2,504,792 shares of the company's stock, valued at approximately $15,053,799.92. The trade was a 2.56% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, insider Stuart A. Tross sold 47,006 shares of the stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $6.33, for a total transaction of $297,547.98. Following the completion of the sale, the insider directly owned 985,007 shares in the company, valued at $6,235,094.31. This trade represents a 4.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 262,846 shares of company stock worth $1,546,840 in the last 90 days. 3.00% of the stock is currently owned by insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Large investors have recently modified their holdings of the business. Freestone Grove Partners LP purchased a new stake in shares of  MannKind in the fourth quarter worth approximately $80,000.  Schonfeld Strategic Advisors LLC grew its position in  MannKind by 179.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 484,162 shares of the biopharmaceutical company's stock valued at $2,745,000 after acquiring an additional 310,894 shares during the last quarter.  Abel Hall LLC bought a new position in  MannKind in the 4th quarter valued at $138,000.  Lazard Asset Management LLC purchased a new stake in  MannKind in the fourth quarter worth $415,000.  Finally, Trexquant Investment LP bought a new stake in shares of  MannKind during the fourth quarter worth $2,534,000. Hedge funds and other institutional investors own  49.55% of the company's stock. </p><h2>About MannKind</h2> (Get Free Report)<p>MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company's core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind's lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.  </p><p>Afrezza received U.S.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than MannKind</li><li>Energy Security Is Now National Security - Positioning Is Happening Now</li><li>Have $500? Invest in Elon’s AI Masterplan</li><li>The gold chart Wall Street is terrified of…</li><li>Your Bank Account Is No Longer Safe</li><li>This $15 Stock Could Go Down as the #1 Stock of 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in MannKind Right Now?</h2><p>Before you consider MannKind, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.</p><p>While MannKind currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MNKD

<p>MannKind (NASDAQ:MNKD) is set to release its Q4 2025 earnings on February 25, with analysts predicting a loss of $0.01 per share. The stock opened at $5.54, with a market cap of $1.70 billion. Recent analyst ratings include a downgrade to "hold" by Zacks and a price target of $11.00 from HC Wainwright. Insider trading shows CEO Michael Castagna sold shares, reducing his stake. Institutional investors hold 49.55% of the company, which specializes in inhaled therapeutic products, notably the Afrezza inhaled insulin for diabetes.</p>

MannKind (MNKD) to Release Earnings on Wednesday